Loading…
Results indicate potential therapeutic benefits for diabetic neuropathy.
MIRA Pharmaceuticals, Inc. announced that its investigational drug, Ketamir-2, has shown efficacy in treating diabetes-associated nerve damage in an animal study. The study results suggest that Ketamir-2 may offer therapeutic benefits for diabetic neuropathy, a common complication of diabetes.
No specific amounts or filings were reported in the announcement. The company's free float stands at 34,944,300 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.